Christine Funke, MD, of Barnet Dulaney Perkins Eye Center, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about combined iDose and iStent infinite treatment for patients with glaucoma and how her patient data supports this treatment option.
Christine Funke, MD:
Hey, Christine Funke, MD, here at ASCRS, and I’m really here to talk about some of my personal data looking at iDose in conjunction with iStent infinite. I’m a huge fan of using multiple MIGS with drug deliverables together, and I really think it’s the idea of synergy, right? We really want to be hitting multiple targets of why IOP may be elevating and try to alter them, and so it’s always really good to look at your data after you’ve done these procedures for a while, most importantly, to make sure that what I’m doing is not just how I feel that I’m doing a good job surgically, but that actually truly we’re getting proven outcomes about how well we are doing in terms of looking at IOP lowering and medication lowering, 2 of the big things that generally we’re looking at when it comes to glaucoma treatment.
What I saw overall, and this is combined data looking at those who are having phacoemulsification with 1 drug deliverable, and then also 3 stents, was that those patients we were seeing somewhere around about a 30% reduction in IOP for that individual group, and then also looking at those who just had a standalone…actually, that reduction was higher, closer to 40%. When we looked at them combined, again, we had a really nice result of IOP lowering, and then also we saw an average of about 1 medication reduction. It made me that much more confident that what I’m doing is really hitting a lot of the targets in terms of pressure reduction and medication reduction.
Then also we have to discuss safety, which the safety profile, we really didn’t see any adverse events looking at these patients. This is over a 3-month period of time. I think still a place to continue to look at them, monitor them, I’ve already been doing that, of looking at our 6-month data and then hopefully 12-month data and then even longer. Because ultimately, what we are doing is we want something that’s going to work well and also have longevity. I think it’s going to be important to have years of data that we are continuing to follow and really understand how well did I do with these specific processes.
Related Content
